Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod Mechanisms in HPV-associated Lesions
NCT00941811Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Dec 2008
- Primary completion
- Dec 2009
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imiquimod in vulvar intraepithelial neoplasia (VIN) and condylomata acuminata, sponsored by Medical University of Vienna. Primary endpoint: Analysis of Cellular and Molecular Mechanisms of Imiquimod treatment and differences in HPV affected and non affected tissue at 16 weeks. Started Dec 2008; status: completed.
02
Drugs
imiquimod
03
Conditions
vulvar intraepithelial neoplasia (VIN)condylomata acuminata
Beyond the preview
Go deeper on NCT00941811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941811.